Surge in Illegal Imports of Obesity Drugs... Growing Need for Discussion on Health Insurance Coverage
Recently, there has been a significant increase in cases of illegal imports of obesity drugs such as Mounjaro and Wegovy into South Korea. According to an announcement by the Korea Customs Service, a total of 4,155 cases of illegal imports were detected in the first half of this year alone. This represents a very rapid increase compared to the 1,189 cases detected throughout all of last year.
This phenomenon is analyzed to be due to the high level of interest and demand for obesity treatments. However, because the prices of these drugs are set higher in South Korea compared to other countries, many consumers are choosing illegal channels such as direct overseas purchases. Experts warn that these methods pose significant risks as they cannot guarantee the safety of the medication.
Some are calling for health insurance to be applied to reduce the financial burden of obesity drugs. Currently, benefits are concentrated only on people with specific conditions such as diabetes, making accessibility for general obesity patients very low. Therefore, the opinion that drug prices should be lowered and official distribution channels should be activated is gaining traction.
It is time for the government and health authorities to strengthen crackdowns to prevent illegal imports while simultaneously initiating social discussions on drug pricing and the scope of health insurance coverage. It is a time when institutional improvements are necessary to ensure the safe use of medication.